Mode
Text Size
Log in / Sign up
Phase 3 N=126 Randomized Quadruple-blind Treatment

Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)

Type 2 Spinal Muscular Atrophy

Enrolled (actual)
126
Serious AEs
29.2%
Results posted
Dec 2025
Primary outcome: Primary: Change From Baseline at the End of Period 1 in the Hammersmith Functional Motor Scale Expanded - Total Score - in the ≥ 2 to < 18 Years Age Group — 2.39; 0.51 Scores on a scale — p=0.0074

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
OAV101 (Genetic); Sham control (Procedure)
Age
Pediatric · 2+ yrs
Sex
All
Sponsor
Novartis Pharmaceuticals
Primary completion
Nov 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline at the End of Period 1 in the Hammersmith Functional Motor Scale Expanded - Total Score - in the ≥ 2 to < 18 Years Age Group
2.39; 0.51 0.0074 sig
SECONDARY
Change From Baseline in HFMSE Total Score at the End of Follow-up Period 1 in Treated Patients Compared to Sham Controls in the ≥ 2 to < 5 Years Age Group
3.00; 1.56 0.1097
SECONDARY
Change From Baseline in Revised Upper Limb Module (RULM) Total Score at the End of Follow-up Period 1 in Treated Patients Compared to Sham Controls in the ≥ 2 to < 18 Years Age Group
2.44; 0.92 0.0122 sig
SECONDARY
Change From Baseline in the RULM Total Score at the End of Follow-up Period 1 in Treated Patients Compared to Sham Controls in the ≥ 2 to < 5 Years Age Group
3.27; 1.82 0.0873
SECONDARY
% of Participants Who Achieved at Least a 3-point Improvement From Baseline in HFMSE Total Score at the End of Follow-up Period 1 in the ≥ 2 to < 18 Years Age Group
39.2; 26.0 0.0879
SECONDARY
% of Participants Who Achieved at Least a 3-point Improvement From Baseline in HFMSE Total Score at the End of Follow-up Period 1 for Participants Aged ≥ 2 to < 5 Years
48.8; 37.9 0.6448
SECONDARY
Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
74; 46; 104; 27; 5; 36
SECONDARY
Number of Participants With Adverse Events of Special Interest (AESI)
7; 5; 10; 4; 2; 9
SECONDARY
Number (and Percentage) of Patients With Intracardiac Thrombi
0; 1; 1
SECONDARY
Number(and Percentage) of Patients With Low Cardiac Function
8; 9; 17

Summary

This was a Phase III multi-center, single dose (1.2 x 10^14 vector genomes), randomized, sham controlled, double-blind study that investigates the efficacy, safety and tolerability of OAV101B in treatment naive, sitting and never ambulatory SMA patients 2 to <18 years of age.

Eligibility Criteria

Key Inclusion criteria

  • Diagnostic confirmation during screening period of 5q SMA
  • The patient must be treatment naive (historical or current use) for all SMN-targeting therapies (e.g., risdiplam (Evrysdi) and nusinersen (Spinraza)).
  • Onset of clinical signs and symptoms at ≥ 6 months of age
  • A complete Hammersmith Functional Motor Scale - Expanded (HFMSE) assessment during the screening period for trial eligibility
  • Able to sit independently at screening, but has never had the ability to walk independently.

Key Exclusion criteria

  • Anti-adeno-associated virus serotype 9 (AAV9) antibody titer reported as elevated (reference to > 1:50 or validated result consistent with being elevated) at screening as determined by sponsor designated lab.
  • Infectious process (e.g., viral, bacterial) or febrile illness within 30 days prior to OAV101 treatment or sham procedure
  • Hepatic dysfunction (i.e. alanine aminotransferase (ALT), total bilirubin, gamma-glutamyl transferase (GGT) or glutamate dehydrogenase (GLDH), > upper limit of normal (ULN).
  • Requiring invasive ventilation, awake noninvasive ventilation for > 6 hours during a 24-hour period, noninvasive ventilation for > 12 hours during a 24-hour period or requiring tracheostomy
  • Complications at screening that would interfere with motor efficacy assessments including but not limited to, severe contractures or Cobb angle > 40 in a sitting position
  • Surgery for scoliosis or hip fixation in the 12 months prior to Screening or planned within the next 64 weeks
  • Clinically significant sensory abnormalities in the neurological examination at Screening
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05089656). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search